UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies

Cancer science, 2016-02, Vol.107 (2), p.107-115

2016

Link zum Volltext

Verfügbarkeit prüfen

Decade in review: a new era for RET-rearranged lung cancers

Translational lung cancer research, 2020-12, Vol.9 (6), p.2571-2580

2020

Link zum Volltext

Verfügbarkeit prüfen

β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells

PloS one, 2015-02, Vol.10 (2), p.e0117097-e0117097

2015

Link zum Volltext

Verfügbarkeit prüfen

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Clinical cancer research, 2021-05, Vol.27 (10), p.2899-2909

2021

Link zum Volltext

Verfügbarkeit prüfen

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

Journal of clinical oncology, 2016-06, Vol.34 (18), p.2165-2171

2016

Link zum Volltext

Verfügbarkeit prüfen

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Clinical cancer research, 2021-05, Vol.27 (10), p.2920-2927

2021

Link zum Volltext

Verfügbarkeit prüfen

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research

Cancer cell, 2021-07, Vol.39 (7), p.897-899

2021

Link zum Volltext

Verfügbarkeit prüfen

Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors

Clinical cancer research, 2022-11, Vol.28 (21), p.4649-4659

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation

Journal of thoracic oncology, 2023-09, Vol.18 (9), p.1222-1232

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.463-475

2023

Link zum Volltext

Verfügbarkeit prüfen

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center

Oncotarget, 2019-10, Vol.10 (56), p.5817-5823

2019

Link zum Volltext

Verfügbarkeit prüfen

Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer

European urology focus, 2016-10, Vol.2 (4), p.445-452

2016

Link zum Volltext

Verfügbarkeit prüfen

Training Oncologists in the Time of COVID‐19

The oncologist (Dayton, Ohio), 2020-07, Vol.25 (7), p.546-547

2020

Link zum Volltext

Verfügbarkeit prüfen

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

JTO clinical and research reports, 2023-08, Vol.4 (8), p.100546-100546, Article 100546

2023

Link zum Volltext

Verfügbarkeit prüfen

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

JTO clinical and research reports, 2021-07, Vol.2 (7), p.100187-100187, Article 100187

2021

Link zum Volltext

Verfügbarkeit prüfen

Pilot Study of Dacomitinib for Patients With Metastatic EGFR -Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

JCO precision oncology, 2021, Vol.5

2021

Link zum Volltext

Verfügbarkeit prüfen

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

Experimental hematology & oncology, 2018-01, Vol.7 (1), p.1-1, Article 1

2018

Link zum Volltext

Verfügbarkeit prüfen

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3062-3062

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21146-e21146

2023

Link zum Volltext

Verfügbarkeit prüfen

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.121-121

2024

Link zum Volltext

Verfügbarkeit prüfen

Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR- mutant lung cancers

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9100-9100

2022

Link zum Volltext

Verfügbarkeit prüfen

Genomic characterization of FGFR -altered solid tumors using a clinically annotated pan-cancer repository

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3074-3074

2023

Link zum Volltext

Verfügbarkeit prüfen

MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3073-3073

2023

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3002-3002

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3697: High PD-L1 expression and targetable mutations occur independently in NSCLC and are not influenced by smoking or race

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3697-3697

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(41)
Buchkapitel
(1)

Sprache

Englisch
(42)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies

Decade in review: a new era for RET-rearranged lung cancers

β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research

Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors

Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center

Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer

Training Oncologists in the Time of COVID‐19

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

Pilot Study of Dacomitinib for Patients With Metastatic EGFR -Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors

Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets)

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)

Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR- mutant lung cancers

Genomic characterization of FGFR -altered solid tumors using a clinically annotated pan-cancer repository

MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer

Abstract 3697: High PD-L1 expression and targetable mutations occur independently in NSCLC and are not influenced by smoking or race

Suchergebnisse filtern